Director/PDMR Shareholding

RNS Number : 7266Y

Hikma Pharmaceuticals Plc

19 May 2016

 

Hikma Pharmaceuticals PLC - Vesting of 2013 LTIP

LONDON, 19 May 2016: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("Hikma") announces that the following Directors and Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards on 17 May 2016 under the 2005 Long Term Incentive Plan ("LTIP") which was completed on 19 May 2016. These awards were automatically exercised by operation of the conditional award and vesting process. The exercise price under the LTIP is £nil. As indicated in the table below, certain PDMRs have made disposals.

In accordance with DTR 3.1.2R and s.793 of the Companies Act 2006, Hikma announces that the following transactions took place in London over Hikma's Ordinary Shares of 10p each ("Shares") as detailed below.

PDMR	Type of Transaction	Shares Acquired under LTIP	Date	Price	Shares Disposed	Remaining Holding
Said Darwazah	Vesting of LTIP 2013	88,383 (0.04% ISC)	19 May 2016	N/A	Nil	13,265,884* (5.54% ISC)
Mazen Darwazah	Vesting of LTIP 2013	45,924 (0.02% ISC)	19 May 2016	N/A	Nil	7,256,131* (3.03% ISC)
Bassam Kanaan	Vesting of LTIP 2013 & Disposal	34,660 (0.01% ISC)	19 May 2016	£22.42	34,660	418,658 (0.19% ISC)
Michael Raya	Vesting of LTIP 2013 & Disposal	32,927 (0.01% ISC)	19 May 2016	£22.42	19,047	133,840 (0.06% ISC)
Riad Mishlawi	Vesting of LTIP 2013	19,063 (0.01% ISC)	19 May 2016	N/A	Nil	119,090 (0.05% ISC)
Khalid Nabilsi	Vesting of LTIP 2013	19,063 (0.01% ISC)	19 May 2016	N/A	Nil	221,921 (0.09% ISC)
Majda Labadi	Vesting of LTIP 2013	14,848 (0.01% ISC)	19 May 2016	N/A	Nil	187,431 (0.08% ISC)
"ISC" = Issued Share Capital of Hikma which is 239,385,501 Shares following the release of the LTIP 2013. * Said Darwazah has a direct interest in Hikma of 745,383 Shares and an effective interest in Hikma through his interest in Darhold Limited of 12,520,501 Shares. Mazen Darwazah has a direct interest in Hikma of 952,965 Shares and an effective interest in Hikma through his interest in Darhold Limited of 6,303,166 Shares.

- ENDS -

Enquiries                                                                                                                                      

Peter Speirs                                                                          [phone]

Company Secretary, Hikma Pharmaceuticals PLC

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.

 

END

 

 

DSHGCGDUSBBBGLC